Compare PKOH & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | NTHI |
|---|---|---|
| Founded | 1907 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 243.9M |
| IPO Year | 1994 | N/A |
| Metric | PKOH | NTHI |
|---|---|---|
| Price | $25.34 | $9.35 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $37.00 | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 38.1K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $1,599,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $17.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.52 | $3.20 |
| 52 Week High | $29.50 | $16.00 |
| Indicator | PKOH | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 49.16 |
| Support Level | $19.01 | $8.29 |
| Resistance Level | $28.50 | $10.96 |
| Average True Range (ATR) | 1.32 | 0.76 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 7.06 | 50.91 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).